Guo X, Li H, Lu X, Liu H, U K, Yan C
Nat Struct Mol Biol. 2024; .
PMID: 39653842
DOI: 10.1038/s41594-024-01439-8.
Shen Q, Murakami K, Sotov V, Butler M, Ohashi P, Reedijk M
Sci Adv. 2024; 10(44):eado8275.
PMID: 39475614
PMC: 11524187.
DOI: 10.1126/sciadv.ado8275.
Hossain F, Ucar D, Monticone G, Ran Y, Majumder S, Larter K
Front Immunol. 2023; 14:1244159.
PMID: 37901240
PMC: 10612326.
DOI: 10.3389/fimmu.2023.1244159.
Xia Q, Shen J, Wang Q, Ke Y, Yan Q, Li H
Front Oncol. 2023; 12:1039366.
PMID: 36620587
PMC: 9815511.
DOI: 10.3389/fonc.2022.1039366.
Jeong S, Park S, Jo Y, Choi M, Lee G, Lee S
Cancers (Basel). 2022; 14(6).
PMID: 35326706
PMC: 8946805.
DOI: 10.3390/cancers14061557.
Mammary Development and Breast Cancer: a Notch Perspective.
Chen W, Wei W, Yu L, Ye Z, Huang F, Zhang L
J Mammary Gland Biol Neoplasia. 2021; 26(3):309-320.
PMID: 34374886
PMC: 8566423.
DOI: 10.1007/s10911-021-09496-1.
GASC1 promotes glioma progression by enhancing NOTCH1 signaling.
Xiao Z, Yang X, Liu Z, Shao Z, Song C, Zhang K
Mol Med Rep. 2021; 23(5).
PMID: 33649841
PMC: 7974312.
DOI: 10.3892/mmr.2021.11949.
ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc.
Cheng Y, Lin L, Li X, Lu A, Hou C, Wu Q
Cancer Cell Int. 2021; 21(1):32.
PMID: 33413403
PMC: 7791678.
DOI: 10.1186/s12935-020-01727-5.
A Molecular Test for Quantifying Functional Notch Signaling Pathway Activity in Human Cancer.
Cante-Barrett K, Holtzer L, van Ooijen H, Hagelaar R, Cordo V, Verhaegh W
Cancers (Basel). 2020; 12(11).
PMID: 33120947
PMC: 7692325.
DOI: 10.3390/cancers12113142.
Retinoic Acid Sensitivity of Triple-Negative Breast Cancer Cells Characterized by Constitutive Activation of the notch1 Pathway: The Role of Rarβ.
Paroni G, Zanetti A, Barzago M, Kurosaki M, Guarrera L, Fratelli M
Cancers (Basel). 2020; 12(10).
PMID: 33081033
PMC: 7650753.
DOI: 10.3390/cancers12103027.
Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Nasser F, Moussa N, Helmy M, Haroun M
Naunyn Schmiedebergs Arch Pharmacol. 2020; 394(3):481-490.
PMID: 33052427
DOI: 10.1007/s00210-020-01988-x.
The mutational landscape of the SCAN-B real-world primary breast cancer transcriptome.
Brueffer C, Gladchuk S, Winter C, Vallon-Christersson J, Hegardt C, Hakkinen J
EMBO Mol Med. 2020; 12(10):e12118.
PMID: 32926574
PMC: 7539222.
DOI: 10.15252/emmm.202012118.
Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells.
Zhu Q, Shen Y, Chen X, He J, Liu J, Zu X
Onco Targets Ther. 2020; 13:525-540.
PMID: 32021295
PMC: 6970631.
DOI: 10.2147/OTT.S224465.
Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios.
Pizzuti L, Krasniqi E, Barchiesi G, Mazzotta M, Barba M, Amodio A
J Cancer. 2019; 10(24):5903-5914.
PMID: 31762800
PMC: 6856581.
DOI: 10.7150/jca.35109.
Notch and breast cancer metastasis: Current knowledge, new sights and targeted therapy.
Zhang Y, Xie Z, Guo X, Xiao X, Xiong L
Oncol Lett. 2019; 18(3):2743-2755.
PMID: 31452752
PMC: 6704289.
DOI: 10.3892/ol.2019.10653.
miR‑125b‑mediated regulation of cell proliferation through the Jagged‑1/Notch signaling pathway by inhibiting BRD4 expression in psoriasis.
Pan M, Huang Y, Zhu X, Lin X, Luo D
Mol Med Rep. 2019; 19(6):5227-5236.
PMID: 31059052
PMC: 6522879.
DOI: 10.3892/mmr.2019.10187.
Notch Signaling Affects Oral Neoplasm Cell Differentiation and Acquisition of Tumor-Specific Characteristics.
Nakano K, Takabatake K, Kawai H, Yoshida S, Maeda H, Kawakami T
Int J Mol Sci. 2019; 20(8).
PMID: 31018488
PMC: 6514842.
DOI: 10.3390/ijms20081973.
Tribbles Homolog 3 Involved in Radiation Response of Triple Negative Breast Cancer Cells by Regulating Notch1 Activation.
Lee Y, Wang W, Chang W, Huang Y, Hong G, Wang H
Cancers (Basel). 2019; 11(2).
PMID: 30678233
PMC: 6406679.
DOI: 10.3390/cancers11020127.
Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.
Polychronidou G, Kotoula V, Manousou K, Kostopoulos I, Karayannopoulou G, Vrettou E
PLoS One. 2018; 13(12):e0208221.
PMID: 30521558
PMC: 6283658.
DOI: 10.1371/journal.pone.0208221.